Vertex Pharmaceuticals Investment Purchases decreased by 8.5% to $1.23B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 43.0%, from $2.16B to $1.23B. Over 4 years (FY 2021 to FY 2025), Investment Purchases shows an upward trend with a 86.5% CAGR.
An increase indicates a surplus of cash being deployed into financial markets rather than core operations; a decrease may suggest a need for liquidity.
The total cash outflow for the acquisition of debt and equity securities, including marketable securities and other fina...
Large-cap technology firms often show high outflows here as they manage massive cash reserves across global portfolios.
cf_purchases_of_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $118.00M | $208.30M | $80.44M | $117.10M | $110.80M | $189.90M | $274.90M | $1.82B | $574.20M | $407.20M | $988.50M | $2.60B | $1.30B | $1.38B | $2.16B | $1.65B | $2.17B | $1.35B | $1.23B |
| QoQ Change | — | +76.5% | -61.4% | +45.6% | -5.4% | +71.4% | +44.8% | +560.8% | -68.4% | -29.1% | +142.8% | +162.9% | -50.1% | +6.8% | +55.9% | -23.7% | +31.9% | -38.1% | -8.5% |
| YoY Change | — | — | — | — | -6.1% | -8.8% | +241.7% | >999% | +418.2% | +114.4% | +259.6% | +43.0% | +125.8% | +240.0% | +118.4% | -36.6% | +67.6% | -2.8% | -43.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.